Chicago / Edinburgh
United States

GINDEX® U.S. Growth Infusion Index

Tracks established companies that have acquired U.S. new listings through full takeovers.

Available for licensing

Use this index in ETFs, mutual funds, structured products or as a benchmark.

Discuss licensing
INDEX PERFORMANCE

Performance history

Total return · USD
As of October 22, 2026

Year to date+17.12%
1 year+18.93%
Since launch+75.01%August 13, 2021
Since launch+75.01%August 13, 2021 – October 22, 2026
100%80%60%40%20%0%-20% Aug 13, 2021Oct 22, 2026
Live index

Total return performance, rebased at the start of the selected period.

INDEX OVERVIEW

About the index

The GINDEX® U.S. Growth Infusion Index (GNDX) follows companies that have acquired a 100% interest in businesses that became publicly traded through a U.S. IPO, direct listing or spin-off. This form of acquisition is described within the IPOX® framework as IPO M&A.

Following innovation through ownership changes

An acquisition can move the products, customers and intellectual property of a recently listed business into an established company. GNDX follows the acquiring companies, connecting the new listings universe with businesses that expand through these transactions.

The approach can span different industries because acquisitions of newly public companies occur across technology, healthcare, financial services, industrials and other sectors. The portfolio's composition follows the transactions and companies that meet the methodology's eligibility criteria.

Equal weighting and quarterly maintenance

The index uses equal weighting. At rebalancing, this gives constituents comparable starting weights; their relative influence can then change as market prices move.

Membership and weights are reviewed quarterly, updating the portfolio as qualifying acquisitions and other relevant changes affect the eligible universe.

Research and index applications

GNDX provides a reference for analyzing acquirers of U.S. new listings and is available for licensed investment products and benchmarking. The dated fact sheet provides portfolio statistics and performance.

The GINDEX® International Growth Infusion Index extends this approach to eligible non-U.S. acquisitions. Full construction and maintenance provisions are available through Rulebook & Regulations.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters